unresectable metastatic/recurrent colorectal cancer
Conditions
Interventions
Bevacizumab was given over 30 min at the first time. If patients had no infusion reaction,the time was shortend to 10 min
Sponsors
Dept of Gastroenterology Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with histologically verified adenocarcinoma of the colon and rectum 2) Patients with Unresectable metastatic/recurrent colorectal cancer 3) Patents without a previous chemotherapy or radiation therapy 4) ECOG Performance status of 0-2
Exclusion criteria
Exclusion criteria: 1) Serious complication (interstitial pneumonitis, pulmonary fibrosis, renal failure, liver failure, poorly-controlled diabetes, poorly-controlled hypertension) 2) Symptomatic or asymptomatic but treated heart disease 3) Active infection. 4) History of serious drug hypersensitivity or a history of drug allergy 5) Brain metastasis 6) Patients with perforated disease 7) Patients with thrombosis 8) Hemorrhagic diathesis, coagulation disorder 9) Pregnant or lactating woman 10) Not appropriate for the study at the physician's assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival The rate of infusion reaction | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of infusion reaction The rate of bevacizumab-induced proteinuria and hypertension | — |
Countries
Japan
Contacts
Public Contactkoihi Taira
Osaka City University Graduate School of Medicine Dept of Gastroenterology
Outcome results
None listed